To identify potential target indications and patient populations that might be sensitive to HER3 inhibition, we profiled the expression of HRG and HER3 in more than 750 individual tumor specimens using a high throughput multiplex qRTPCR system [18]. This evidence concerns the gene ERBB3 and neoplasm.